Our recent study clarified that several A disintegrin and metalloproteases (ADAMs), including ADAM9, are MICA sheddases that are involved in HCC and that the suppression of ADAMs demonstrates the rationality to enhance MICA-NK-targeted therapy [7]. Here, MICA is linked to hepatocellular carcinoma.